CN108276444A - 一类新的化合物及其用途 - Google Patents
一类新的化合物及其用途 Download PDFInfo
- Publication number
- CN108276444A CN108276444A CN201710011150.6A CN201710011150A CN108276444A CN 108276444 A CN108276444 A CN 108276444A CN 201710011150 A CN201710011150 A CN 201710011150A CN 108276444 A CN108276444 A CN 108276444A
- Authority
- CN
- China
- Prior art keywords
- heterocycle
- compound
- alkynyl
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 239000003443 antiviral agent Substances 0.000 claims abstract description 5
- 241000700605 Viruses Species 0.000 claims description 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- -1 substituted-phenyl Chemical group 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000003342 alkenyl group Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 208000002672 hepatitis B Diseases 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960004556 tenofovir Drugs 0.000 description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 0 Cc1nc(*)c2nc[n](CC3(CC3)OCP(*)(O)=[U])c2n1 Chemical compound Cc1nc(*)c2nc[n](CC3(CC3)OCP(*)(O)=[U])c2n1 0.000 description 1
- 108091036055 CccDNA Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036141 Viral hepatitis carrier Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一类新的化合物及其用途,还涉及该类化合物在制备抗病毒药物等方面的应用。
Description
技术领域
本发明涉及一类新的化合物及其用途,还涉及该类化合物在制备抗病毒药物等方面的应用。
背景技术
人类免疫缺陷病毒(Human Immunodeficiency Virus;abbr:HIV),即艾滋病(AIDS,获得性免疫缺陷综合征)病毒,是造成人类免疫系统缺陷的一种病毒。1981年,人类免疫缺陷病毒在美国首次发现。它是一种感染人类免疫系统细胞的慢病毒(Lentivirus),属逆转录病毒的一种。
HIV通过破坏人体的T淋巴细胞,进而阻断细胞免疫和体液免疫过程,导致免疫系统瘫痪,从而致使各种疾病在人体内蔓延,最终导致艾滋病。由于HIV的变异极其迅速,难以生产特异性疫苗,至今无有效治疗方法,对人类健康造成极大威胁。
HBV(乙型肝炎病毒)简称乙肝病毒。是一种DNA病毒,属于嗜肝DNA病毒科(hepadnaviridae)。根据目前所知,HBV就只对人和猩猩有易感性,引发乙型病毒性肝炎疾病。完整的乙肝病毒成颗粒状,也会被称为丹娜颗粒(Dane)。1965年由丹娜发现。直径为42纳米。颗粒分为外壳和核心两部分。
我国的乙肝病毒感染率约60%-70%;乙肝表面抗原携带率约占总人口的7.18%,以此计算,全国约有9300万人携带乙肝病毒,其中慢性乙型肝炎患者约2000万例。
HIV-1和HBV药物的研发一直以来都是药物研发的重点和热点之一。
发明内容
本发明的发明人在研制新的HIV-1和HBV抗病毒药物的过程中,意外地发现一类新化合物,该类化合物出人意料地具有优异的抗HIV-1和HBV病毒活性。
为了完成本发明的目的,本发明提供一类新的化合物及其用途,经过药理实验发现,该类新化合物在抗病毒药理实验中,效果显著。现有技术中未见对该类化合物的报道。
该类新化合物为通式A1的化合物,或其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其结构通式如下:
通式A1:
R1为氢、OH、SH、CN、卤素、C1-C7烷基、C2-C6烯基、C2-C6炔基、OR6或NR7R8。
R2、R3分别为氢、卤素、CN、N3、SH、OH、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基、C2-C6炔基、OR6或NR7R8。
或者R2、R3相连以形成3-7元环烷基或含有选自N、O、S、Se的3-7元杂环基。
R4为ZR9XR10、ZR10。
R5为OH、SH、-NR11R12COOR13 -OR14OCOOR15 或-OR14OCOR15
W、Z、X分别为O、S或Se。
R6、R7、R8分别为氢、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基。
R9为C1-C40亚烷基、C1-C40取代亚烷基、亚环烷基、取代亚环烷基、亚杂环基、取代亚杂环基、亚烯基、取代亚烯基、亚炔基或取代亚炔基。
R10为C1-C40烷基、C1-C40取代烷基、环烷基、取代环烷基、杂环基、取代杂环基、烯基、取代烯基、炔基、取代炔基、苯基、取代苯基、苄基、取代苄基、杂环基、取代杂环基、芳基、取代芳基、杂芳基或取代杂芳基。
R11、R14分别为C1-C7亚烷基、C3-C7亚环烷基、C3-C7亚杂环基、C2-C6亚烯基或C2-C6亚炔基。
R12为氢、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基。
R13、R15分别为C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基。
通式A1进一步优选为A2-A5,结构通式如下:
A2:
A3:
A4:
A5:
A6:
R1为H、OH。
R5为OH、
m=1-39,n=1-39。
通过进一步优化,可以优化为表1中各化合物,其结构式如下:
表1:
以上本发明各结构通式及结构式的详细描述,不应被认为是对本发明的限制。
部分新化合物的制备方法如下:
新化合物M15的制备方法:
新化合物M16的制备方法:
新化合物M19的制备方法:
新化合物M20的制备方法:
新化合物M24的制备方法:
新化合物M25的制备方法:
新化合物M26的制备方法:
新化合物M27的制备方法:
新化合物M28的制备方法:
新化合物M31的制备方法:
新化合物M32的制备方法:
新化合物M34的制备方法:
新化合物M35的制备方法:
新化合物M37的制备方法:
新化合物M38的制备方法:
新化合物M51的制备方法:
本发明还提供上述新的化合物在制备抗病毒药物中的应用。特别的,该化合物用于制备抗艾滋病病毒和/或抗乙肝病毒的药物中。
本发明采用细胞培养法测定了本发明化合物M15、M16、M27、M28、M31、M32、M34、M35、M51的体外抗病毒活性,结果表明,本发明各化合物对逆转录病毒HIV-1和HBV的抑制作用均较强。各化合物的抗HIV-1和抗HBV药理活性均强于替诺福韦艾拉酚胺(TAF)。
具体实施方式
下面以实施例的方式对本发明做进一步的详细说明,给出本发明的实施细节,但是不应被认为是对本发明的限制。
本发明的化合物抗病毒活性检测:
实施例1:HIV活性测试
将293T细胞按每孔6×104的密度加到24孔板上,用DMSO溶解待测化合物,并配制不同的浓度,于感染前15分钟加入细胞培养液中,DMSO溶剂作空白对照,再加入0.5ml病毒液(根据p24浓度将病毒原液稀释至0.1-0.5ng p24/ml)。感染后48小时,去除上清液,每孔中加入50μl细胞裂解液(Promega)裂解细胞,再将20μl细胞裂解产物加入至30μl荧光素酶底物中(Promega),用FB15荧光检测器(Sirius)仪器测定细胞荧光素酶的相对活性,以DMSO作对照,计算化合物对野生型HIV-1复制的半数抑制浓度。
将对数生长期的293T细胞按8000~10000个/孔的细胞密度接种至96孔板中,每孔100ul,37℃,5%CO2培养箱中培养24h后,加入待测化合物,并以DMSO为空白对照(终浓度为0.1%),37℃,5%CO2培养箱中继续培养44小时。向每孔中加入20μlMTS/PMS现配的混合液,37℃,5%CO2培养箱中继续培养4小时后显色。在酶联检测仪上,波长490nm和650nm处检测各孔的光吸收值(OD),在Victor3V1420多标记记数器(Perkin Elmer)中检测板的突光,应用Microsoft Excel和XLfit4.1软件求出CC50值。
合成化合物的抗HIV活性评价:
实验结果显示,新化合物都有很强的抗HIV活性。和替诺福韦艾拉酚胺(TAF)的抗HIV活性对比,化合物M15、M16、M27、M28、M31、M32、M34、M35、M51都显示了更高的活性。
实施例2:合成化合物的抗HBV活性评价:
HepG2 2.2.15细胞(SELLS,PNAS,1987andSELLS,JV,1988)的染色体整合有完整的HBV基因组,并稳定表达病毒RNA,cccDNA和病毒蛋白质。此外,该细胞还向培养基中分泌成熟的乙肝病毒颗粒。通过qPCR量化病毒粒子DNA的方法可以测量病毒的复制。待测化合物用DMSO溶解为30mM的储存液并保存在-20℃。在96孔细胞培养板中加入每孔10,000个HepG22.2.15细胞,每孔200μL细胞培养基,在37℃,5%CO2细胞培养箱中培养3天至细胞长满。弃掉旧的培养基并加入200μL新鲜的检测培养基(5%FBS)。加入100%DMSO稀释的化合物1μL:稀释为不同的指定的测试浓度,在CO2培养箱中孵育10天,每隔一天(第2,4,6,8,10天)换一次液(5%FBS),并加入新鲜配制浓度的化合物。在第11天每孔取150μL上清提取病毒DNA。细胞毒性检测板也进行类似处理:最高浓度是150μM。病毒基因组DNA的提取试剂盒为QIAamp96DNA Blood Kit。经过常规的离心和QPCR过程。用包含HBV基因组的质粒(病毒拷贝数:2*10E6,2*10E5,2*10E4,2*10E3)做标准曲线,并以标准曲线来计算病毒拷贝数。抑制率的计算公式如下:抗病毒的抑制率=100-(检测值-HPE平均值)/(ZPE平均值-HPE平均值)*100(ZPE:最低浓度化合物孔平均值,HPE:最高浓度化合物孔平均值)。抑制率数据通过Graphpad Prism 5软件处理并绘制曲线,EC50和EC90通过四参数非线性回归模型计算。细胞毒性%=100-(检测值/DMSO对照孔平均值*100)。细胞毒性%数据通过Graphpad Prism 5软件处理并绘制曲线,CC50通过四参数非线性回归模型计算。
化合物的抗HBV活性评价:
实验结果显示,所有的新化合物都有很强的抗HBV活性。和替诺福韦艾拉酚胺(TAF)比较,新化合物M15、M16、M27、M28、M31、M32、M34、M35、M51都显示了更优秀的活性。
Claims (5)
1.一类新的化合物及其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其特征在于,其结构通式为:
通式A1:
R1为氢、OH、SH、CN、卤素、C1-C7烷基、C2-C6烯基、C2-C6炔基、OR6或NR7R8;
R2、R3分别为氢、卤素、CN、N3、SH、OH、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基、C2-C6炔基或OR6、NR7R8;
或者R2、R3相连以形成3-7元环烷基或含有选自N、O、S、Se的3-7元杂环基;
R4为ZR9XR10或ZR10;
R5为OH、SH、-NR11R12COOR13 -OR14OCOOR15 或-OR14OCOR15
W、Z、X分别为O、S或Se;
R6、R7、R8分别为氢、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基;
R9为C1-C40亚烷基、C1-C40取代亚烷基、亚环烷基、取代亚环烷基、亚杂环基、取代亚杂环基、亚烯基、取代亚烯基、亚炔基或取代亚炔基;
R10为C1-C40烷基、C1-C40取代烷基、环烷基、取代环烷基、杂环基、取代杂环基、烯基、取代烯基、炔基、取代炔基、苯基、取代苯基、苄基、取代苄基、杂环基、取代杂环基、芳基、取代芳基、杂芳基或取代杂芳基;
R11、R14分别为C1-C7亚烷基、C3-C7亚环烷基、C3-C7亚杂环基、C2-C6亚烯基或C2-C6亚炔基;
R12为氢、C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基;
R13、R15分别为C1-C7烷基、C3-C7环烷基、C3-C7杂环基、C6-C10芳基、C6-C10杂芳基、C2-C6烯基或C2-C6炔基。
2.根据权利要求1的化合物,或其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其特征在于,其结构通式为下述通式中的任一种:
通式A2:
通式A3:
通式A4:
A5:
R1为H或OH;
R5为OH、
m=1-39,n=1-39。
3.根据权利要求1或2所述的化合物,或其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其特征在于,其结构式为下述结构式中的任一种:
4.根据权利要求1-3任一项所述的化合物,或其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其特征在于,该化合物用于制备抗病毒药物中。
5.根据权利要求4所述的化合物,或其立体异构体,药学上可接受的盐和/或水合物、溶剂合物或晶型,其特征在于,该化合物用于制备抗艾滋病病毒和/或抗乙肝病毒的药物中。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710011150.6A CN108276444A (zh) | 2017-01-06 | 2017-01-06 | 一类新的化合物及其用途 |
PCT/CN2017/119709 WO2018126994A1 (zh) | 2017-01-06 | 2017-12-29 | 一类新的化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710011150.6A CN108276444A (zh) | 2017-01-06 | 2017-01-06 | 一类新的化合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108276444A true CN108276444A (zh) | 2018-07-13 |
Family
ID=62789075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710011150.6A Pending CN108276444A (zh) | 2017-01-06 | 2017-01-06 | 一类新的化合物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108276444A (zh) |
WO (1) | WO2018126994A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950383A (zh) * | 2003-12-30 | 2007-04-18 | 吉里德科学公司 | 用于治疗病毒性疾病的膦酸酯、单膦酸酰胺化物、双膦酸酰胺化物 |
CN104098563A (zh) * | 2013-04-02 | 2014-10-15 | 山东亨利医药科技有限责任公司 | Jnk抑制剂化合物 |
CN104119385A (zh) * | 2014-07-24 | 2014-10-29 | 廖国超 | 核苷类似物的磷酸酯前药及其应用 |
CN105246902A (zh) * | 2013-03-15 | 2016-01-13 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
WO2016044281A1 (en) * | 2014-09-15 | 2016-03-24 | The Regents Of The University Of California | Nucleotide analogs |
CN107849074A (zh) * | 2016-01-19 | 2018-03-27 | 四川海思科制药有限公司 | 一种核苷类似物的烷氧烷基酯前药及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
-
2017
- 2017-01-06 CN CN201710011150.6A patent/CN108276444A/zh active Pending
- 2017-12-29 WO PCT/CN2017/119709 patent/WO2018126994A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1950383A (zh) * | 2003-12-30 | 2007-04-18 | 吉里德科学公司 | 用于治疗病毒性疾病的膦酸酯、单膦酸酰胺化物、双膦酸酰胺化物 |
CN105246902A (zh) * | 2013-03-15 | 2016-01-13 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
CN104098563A (zh) * | 2013-04-02 | 2014-10-15 | 山东亨利医药科技有限责任公司 | Jnk抑制剂化合物 |
CN104119385A (zh) * | 2014-07-24 | 2014-10-29 | 廖国超 | 核苷类似物的磷酸酯前药及其应用 |
WO2016044281A1 (en) * | 2014-09-15 | 2016-03-24 | The Regents Of The University Of California | Nucleotide analogs |
CN107849074A (zh) * | 2016-01-19 | 2018-03-27 | 四川海思科制药有限公司 | 一种核苷类似物的烷氧烷基酯前药及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2018126994A1 (zh) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Clercq et al. | Approved antiviral drugs over the past 50 years | |
Valiente‐Echeverría et al. | RNA helicase DDX3: at the crossroad of viral replication and antiviral immunity | |
US9533990B2 (en) | Inhibitors of secretion of hepatitis B virus antigens | |
Cobos Jiménez et al. | Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons | |
Sommer et al. | Restrictive influence of SAMHD1 on Hepatitis B Virus life cycle | |
Dussupt et al. | Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding | |
Garbelli et al. | Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication | |
Chen et al. | CRISPR-Cas targeting of host genes as an antiviral strategy | |
Wang et al. | Inhibition of HIV-1 maturation via small-molecule targeting of the amino-terminal domain in the viral capsid protein | |
Visalli et al. | Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication | |
CN109053803A (zh) | 一类新的化合物及其用途 | |
CN108912172A (zh) | 一类新的化合物及其用途 | |
CN109096335A (zh) | 一类新的化合物及其用途 | |
CN108276444A (zh) | 一类新的化合物及其用途 | |
Fischer et al. | CA mutation N57A has distinct strain-specific HIV-1 capsid uncoating and infectivity phenotypes | |
Cordeil et al. | Evidence for a different susceptibility of primate lentiviruses to type I interferons | |
CN108276443A (zh) | 一种新的化合物及其用途 | |
Koh et al. | Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity | |
Fujita et al. | Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif | |
CN113354684A (zh) | 一类新的化合物及其用途 | |
CN108948085A (zh) | 一类新的化合物及其用途 | |
Zahoor et al. | NF-κB inhibition facilitates the establishment of cell lines that chronically produce human T-lymphotropic virus type 1 viral particles | |
Lane et al. | N-Phenyl-1-(phenylsulfonyl)-1 H-1, 2, 4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor | |
CN109467573A (zh) | 一类抗病毒的化合物及其用途 | |
Wang et al. | Human immunodeficiency virus-1 core: The Trojan horse in virus–host interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180713 |